Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

JCI Editorial Board
potential first-tier conflicts of interest

Updated March 3, 2025

Go to the JCI's conflict-of-interest policy

 

AbbVie (S.E. Quaggin)

AccureX (D. Krainc)

Alnylam (A.B. Heimberger)

Aplexis Inc. (P. Ji)

Arvinas (M. Hussain)

AstraZeneca (M. Hussain)

Bayer (M. Hussain)

Biofluid Technology (E.M. McNally)

Biohaven Pharmaceuticals Inc. (A.L. George Jr.)

BioMed Central (H. Perlman)

Calidi Biotherapeutics (M.S. Lesniak)

Caris Life Sciences (A.B. Heimberger)

Cell IDx (E.M. McNally)

Cytokinetics (E.M. McNally)

Gateway Biome (E.B. Chang)

Ikaika Therapeutics (E.M. McNally)

Inomagen Therapeutics (R.K. Arora)

Ionis (J. Bass)

Lakeside Discovery (E.M. McNally, A. Shilatifard)

Leal Therapeutics (D. Krainc)

Leducq Foundation (H. Ardehali)

Lung Healing Technologies (A. Bharat)

Lung IQ LLC (A. Bharat)

Mannin Research Inc. (S.E. Quaggin)

Medtronic (J. Bass)

Michael J. Fox Foundation (D. Krainc)

Moonlight Bio (J. Choi)

Nfold (S. Eisenbarth)

Oligo Foundry (E.M. McNally)

Omega Therapeutics (A. Shilatifard)

OrbiMed (D. Krainc)

PepGen (E.M. McNally)

Pfizer (N.S. Chandel, E.M. McNally)

Pyxis Oncology (M.L. Alegre)

Rafael Pharmaceuticals (N.S. Chandel)

Regeneron (J. Bass)

Riptide LLC (E.M. McNally)

Servier Laboratories (A.B. Heimberger)

Tenaya Therapeutics (E.M. McNally)

Thermo Fisher Scientific (J. Bass)

Three Squared Biosciences (E.B. Chang)

Vanqua Bio (D. Krainc)

Vertex Pharmaceuticals (J. Bass)

Visiongate LLC (A. Bharat)

Vortex Therapeutics (S.A. Abdulkadir)

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts